{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit not calculated due to insufficient number of events","groupId":"OG000","lowerLimit":"300.4","upperLimit":"NA","value":"NA"},{"comment":"Median and upper limit not calculated due to insufficient number of events","groupId":"OG001","lowerLimit":"283.4","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"description":"Time to next anti-lymphoma treatment is defined as the time from the first dose date of maintenance therapy to the time of first documented administration of new anti-lymphoma therapy. Participants without new treatment therapy will be censored at the last visit. Analysis was based on Kaplan Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Maintenance Period (18 Cycles): lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle for Cycles 13 to 30 AND rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29. Followed by Optional Maintenance Period (up to PD): Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle up to PD. This treatment will be at the discretion of the participant and the investigator.","id":"OG000","title":"Arm A: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): participants received rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29","id":"OG001","title":"Arm B: Rituximab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants in Arm A and Arm B, as prespecified in the protocol","reportingStatus":"POSTED","timeFrame":"From the first dose date of maintenance therapy to the time of first documented administration of new anti-lymphoma therapy (up to approximately 300 weeks)","title":"Time to Next Anti-lymphoma Treatment","type":"SECONDARY","unitOfMeasure":"Weeks"}